Phytomedicine, Journal Year: 2025, Volume and Issue: unknown, P. 156873 - 156873
Published: May 1, 2025
Language: Английский
Pharmacological Research, Journal Year: 2025, Volume and Issue: unknown, P. 107769 - 107769
Published: May 1, 2025
The development of synthetic modulators for human free fatty acid receptors (FFARs) has gained attention addressing diabetes, metabolic syndrome, and dyslipidaemia. A new dual FFAR1 (GPR40) FFAR4 (GPR120) agonist, DFL23916, was recently identified to improve glucose homeostasis, prompting investigations into its effects on disorders. This study assessed the selectivity toxicity DFL23916 in vitro evaluated vivo using Drosophila melanogaster models high-sugar (HSD) high-fat diets (HFD). showed no off-target activities with toxicity/hepatotoxicity cultured cells. In adult HSD-fed flies defective mobility, oral administration enhanced climbing speed a concentration-dependent manner reduced high content triglyceride levels alongside markers insulin resistance. compound did not affect viability food intake exposed chronic overcaloric conditions but it inhibited progressive weight gain. Similarly, larvae remained unaffected by while counteracted elevation lipid droplet size caused HSD HFD. Finally, silico analysis highlighted relevance evolutionary conserved sensing, suggesting putative candidates binding. Collectively, these findings indicated safe profile efficacy ameliorating hyperglycaemic hyperlipidaemic features fed flies. Our results only suggest that could be potential candidate further investigation context disorders also reinforce D. as valuable model preclinical evaluation interventions, including FFAR-targeting strategies.
Language: Английский
Citations
0
Letters in Drug Design & Discovery, Journal Year: 2025, Volume and Issue: unknown, P. 100012 - 100012
Published: May 1, 2025
Language: Английский
Citations
0
Frontiers in Endocrinology, Journal Year: 2025, Volume and Issue: 16
Published: May 15, 2025
Type 1 diabetes (T1D) is an autoimmune disease characterized by T cell-mediated destruction of pancreatic β-cells and one the most common chronic diseases in adults children. In recent years, incidence T1D has been increasing worldwide. Currently, diagnosis relies on clinical manifestations autoantibody detection, with a lack early predictive biomarkers. MicroRNAs (miRNAs), as crucial post-transcriptional regulatory factors, which are involved various biological processes, including cell division, proliferation, differentiation, development, metabolism. Additionally, miRNAs participate regulation inflammatory complications T1D, their aberrant expression closely associated disease. The stability makes them potential candidates for diagnostic biomarkers therapeutic targets T1D. This paper discusses pathogenesis applications interventional therapy. It provides references advancing precision personalized treatment strategies through more profound miRNA research future.
Language: Английский
Citations
0
Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16
Published: May 16, 2025
Regulatory immune cells are pivotal in maintaining homeostasis and modulating responses to prevent pathologies. While T regulatory (Tregs) extensively recognized for their immunosuppressive roles, emerging subsets of cells, including CD8+ (CD8+Tregs) B (Bregs), myeloid-derived suppressor (MDSCs), dendritic (DCregs), innate lymphoid (ILCregs), natural killer (NKregs), garnering increased attention. This review delves into the phenotypic characteristics, mechanisms action, immune-regulatory functions these lesser-known but crucial cell subsets. The provides a comprehensive examination each type, detailing origins, unique functionalities, contributions homeostasis. It emphasizes complex interplay among how coordinated activities influence diverse pathological therapeutic contexts, autoimmunity, cancer immunotherapy, chronic inflammation, transplant tolerance. By unraveling mechanisms, outlines novel avenues, such as targeting modulate activity enhance precision medicine approaches. future immunotherapy modulation lies leveraging expanded knowledge presenting challenges opportunities clinical applications.
Language: Английский
Citations
0
Phytomedicine, Journal Year: 2025, Volume and Issue: unknown, P. 156873 - 156873
Published: May 1, 2025
Language: Английский
Citations
0